122 related articles for article (PubMed ID: 32643402)
1. Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer.
He Y; Gong R; Peng KW; Liu LZ; Sun LY; Wang HY
Biomark Med; 2020 Jun; 14(9):717-726. PubMed ID: 32643402
[No Abstract] [Full Text] [Related]
2. Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer.
Okugawa Y; Toiyama Y; Yamamoto A; Shigemori T; Ide S; Kitajima T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Yokoe T; Saigusa S; Tanaka K; Shirai Y; Kobayashi M; Ohi M; Araki T; McMillan DC; Miki C; Goel A; Kusunoki M
Ann Surg; 2020 Aug; 272(2):342-351. PubMed ID: 32675548
[TBL] [Abstract][Full Text] [Related]
3. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
4. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
[TBL] [Abstract][Full Text] [Related]
7. Combined C-reactive protein and Neutrophil to Lymphocyte ratio use predict survival innon-small-cell lung cancer.
Bacha S; Sghaier A; Habibech S; Cheikhrouhou S; Racil H; Chaouch N; Zaouri B; Chabbou A
Tunis Med; 2017 Dec; 95(12):229-235. PubMed ID: 29878284
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer.
Suzuki S; Akiyoshi T; Oba K; Otsuka F; Tominaga T; Nagasaki T; Fukunaga Y; Ueno M
Ann Surg Oncol; 2020 Mar; 27(3):844-852. PubMed ID: 31720937
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer.
Okugawa Y; Toiyama Y; Yamamoto A; Shigemori T; Ichikawa T; Yin C; Suzuki A; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; McMillan DC; Kusunoki M
Clin Nutr; 2020 Apr; 39(4):1209-1217. PubMed ID: 31155370
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study.
Cheng CB; Zhang QX; Zhuang LP; Sun JW
Jpn J Clin Oncol; 2020 Sep; 50(10):1141-1149. PubMed ID: 32564084
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of lymphocyte to C-reactive protein ratio in predicting survival and postoperative complication for esophago-gastric junction cancer.
Tsujiura M; Yamamoto A; Imaoka H; Shimura T; Kitajima T; Morimoto Y; Kawamura M; Yasuda H; Okita Y; Yokoe T; Okugawa Y; Ohi M; Toiyama Y
Surg Oncol; 2022 Sep; 44():101842. PubMed ID: 36081281
[TBL] [Abstract][Full Text] [Related]
15. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of the preoperative lymphocyte C-reactive protein ratio in esophageal cancer patients.
Yamamoto A; Toiyama Y; Okugawa Y; Ichikawa T; Imaoka H; Yasuda H; Fujikawa H; Okita Y; Yokoe T; Ohi M
Surg Today; 2021 May; 51(5):745-755. PubMed ID: 33130991
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Pretreatment: Lymphocyte-to-Monocyte Ratio in Patients With Rectal Cancer Receiving Preoperative Chemoradiotherapy.
Yamamoto A; Toiyama Y; Okugawa Y; Oki S; Ide S; Saigusa S; Araki T; Kusunoki M
Dis Colon Rectum; 2019 Feb; 62(2):171-180. PubMed ID: 30451750
[TBL] [Abstract][Full Text] [Related]
18. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer?
Angin YS; Yildirim M; Dasiran F; Okan I
ANZ J Surg; 2021 Jul; 91(7-8):1521-1527. PubMed ID: 33956378
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte-C-reactive protein ratio with calf circumference could better predict survival of patients with non-metastatic cancer.
Liu XY; Zhang X; Zhang Q; Ruan GT; Xie HL; Liu T; Song MM; Ge YZ; Deng L; Shi HP
Sci Rep; 2023 May; 13(1):7217. PubMed ID: 37137949
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
